
Background: Although numerous observational studies suggest that higher vitamin D levels are associated with a reduced risk of breast cancer, the overall evidence remains inconclusive. This study aimed to comprehensively evaluate this association through a systematic review and meta-analysis.Methods: A systematic literature search was conducted in PubMed, Scopus, and Google Scholar up to February 16, 2024. Relevant articles were extracted, and title and abstract screening followed by full-text screening was carried out. Quality assessment was followed by data extraction and analysis for selected articles. All pooled analyses were performed on the natural log scale and exponentiated to obtain valid odds ratios (ORs).Results: Nineteen case-control studies, comprising 12 541 cases and 29 272 controls, were included. Lower circulating vitamin D levels were significantly associated with an increased risk of breast cancer (OR, 1.70; 95% CI, 1.31–2.23; P < .001). Between-study heterogeneity was high (I2 = 96.4%). In a prespecified subgroup analysis by study design, nested case-control studies showed a modest but statistically significant increase in risk (OR, 1.20; 95% CI, 1.06–1.36; I2 = 0.0%), whereas retrospective studies showed a larger but highly heterogeneous increase in risk (OR, 2.06; 95% CI, 1.38–3.08; I2 = 98.1%).Conclusions: This meta-analysis, using a harmonized log-scale approach, supports a significant inverse association between vitamin D levels and breast cancer risk. The most reliable evidence from nested case-control studies suggests a modest increase in risk, while retrospective studies likely overestimate the association due to reverse causality. Further well-designed prospective studies are warranted.
Background: Granulomatous mastitis (GM) is a rare benign inflammatory breast disease that can mimic breast carcinoma and infectious mastitis. Breast abscess at initial presentation may indicate a more active inflammatory phenotype and influence management. We aimed to describe histologically confirmed GM and explore features associated with baseline breast abscess.Methods: We conducted a retrospective single-center case series using the pathology archives of Abderrahman Mami Hospital from January 1, 2004, to February 29, 2024. Data were extracted from records and supplemented by direct patient contact when necessary. Patients were compared according to breast abscess status at initial presentation.Results: The study population comprised 42 patients, with a mean (standard deviation [SD]) age of 50.2 (11.0) years and a mean (SD) body mass index (BMI) of 25.2 (2.6). Breast abscess was present in 12 patients (28.6%). Neutrophilic infiltrates were more frequent in the abscess group than in the nonabscess group (83.3% vs 10.0%; odds ratio [OR], 45.00; 95% confidence interval [CI], 6.53–310.26; P < .001). Microabscesses were also associated with abscess presentation (66.7% vs 16.7%; OR, 10.00; 95% CI, 2.15–46.51; P = .003). In the adjusted model, higher BMI was associated with baseline abscess presentation (adjusted OR, 1.70 per 1-unit increase in BMI; 95% CI, 1.01–2.84; P = .04).Conclusion: In this retrospective series, breast abscess at initial presentation was associated with a more suppurative histopathological profile and a higher BMI in the adjusted exploratory model. Prospective multicenter validation is required.
Background: Circulating microRNAs are promising noninvasive biomarkers in oncology. Notable gaps remain in relevant serum-focused research on early-stage breast cancer; therefore, this study integrated transcriptomic data to identify a signature with both diagnostic and prognostic value.Methods: We retrieved serum microRNA data from the publicly available microarray data set GSE73002, which includes 1270 patients with early-stage breast cancer and 2686 healthy controls. We used limma’s empirical Bayes method to analyze differential expression, predicted target genes using miRWalk, performed functional enrichment analysis, and assessed prognostic relevance using survival data from the TCGA-BRCA tissue cohort as a supportive, non-independent line of evidence.Results: At an FDR threshold of 0.05, we identified 1450 upregulated microRNAs and 898 downregulated microRNAs. Core upregulated microRNAs, including hsa-miR-614, showed enrichment of predicted target genes, and high hsa-miR-614 expression was associated with shorter overall survival (HR, 2.81; 95% CI, 1.24-6.39; P = .0098).Conclusion: Early breast tumorigenesis may be characterized by systemic dysregulation of circulating microRNAs that govern epigenetic and transcriptional networks. These specific signatures, notably hsa-miR-614, may serve as promising candidates for liquid biopsy-based diagnostic and prognostic biomarkers, pending further experimental and prospective clinical validation. The survival association reported here was derived from a tissue-based cohort (TCGA-BRCA) and should be interpreted as supportive evidence rather than independent validation in circulating samples; prospective studies using independent serum or plasma cohorts are needed to confirm prognostic utility in liquid biopsy settings.
Background: Breast cancer remains the most frequently diagnosed malignancy in women worldwide, and its clinical heterogeneity imposes formidable challenges on treatment standardization and outcome prediction. The emergence of artificial intelligence (AI) and multimodal data integration strategies is fundamentally reshaping how genomic, histopathological, radiological, and electronic health record (EHR) data are synthesized into actionable clinical intelligence.Methods: We conducted a narrative review of peer-reviewed literature published between 2015 and 2026, focusing on AI-driven approaches to genomic profiling, digital pathology, radiomics, natural language processing (NLP) of clinical text, and multimodal data fusion in the context of breast cancer diagnosis, prognosis, and treatment planning.Results: AI-based frameworks have demonstrated superior performance compared with conventional single-modality approaches in subtype classification, treatment response prediction, and biomarker discovery. Deep learning architectures applied to whole-slide imaging, convolutional neural networks in radiomics, graph-based genomic models, and transformer-based NLP pipelines each contribute distinct and complementary dimensions to precision breast oncology. Multimodal fusion models integrating 2 or more data streams consistently outperform unimodal counterparts in prognostic accuracy.Conclusions: Multimodal AI represents a convergent approach capable of operationalizing the biological complexity of breast cancer at the point of clinical care. Realizing this potential requires rigorous prospective validation, harmonized data standards, explainability frameworks, and equitable implementation strategies. Future models must be adaptive, continuously learning, and grounded in real-world clinical evidence.
Background: Early breast cancer is characterized by subtle molecular alterations that may escape detection by conventional single-marker assays. Liquid biopsy offers a non-invasive approach to capturing this complexity, yet most circulating biomarker studies remain limited to a single molecular layer. This study aimed to develop and evaluate an integrated circulating signature combining microRNAs, EPCAM-associated epithelial dissemination signals, and tumor-associated serum proteins for early breast cancer detection in Iraqi women. Methods: This case–control study included 75 women (25 patients with early breast cancer and 50 healthy controls) recruited at the National Hospital for Oncology and Hematology, Najaf, Iraq, between February and August 2025. Three computationally prioritized circulating miRNAs (hsa-miR-4734, hsa-miR-5787, hsa-miR-4532) identified from the public serum-miRNA dataset GSE73002 were quantified by SYBR-Green qRT-PCR using hsa-miR-16 as reference. EPCAM expression was assessed by qPCR with GAPDH normalization in a subset of 13 subjects. Serum CA15-3, CEA, and mammaglobin-1 (MGB1) were measured by sandwich ELISA. An integrated multi-marker classifier was constructed using leave-one-out cross-validated logistic regression. Results: hsa-miR-4734 (4.2-fold; p=0.0005, AUC 0.75), hsa-miR-5787 (4.0-fold; p=0.013, AUC 0.68), and hsa-miR-4532 (5.0-fold; p=0.087, AUC 0.62) were upregulated in patients. EPCAM expression was also elevated in a 13-subject subset (7 patients, 6 controls; p=0.043, AUC 0.86, 95% CI 0.50–0.97). The integrated five-marker classifier achieved a leave-one-out cross-validated AUC of 0.91 (95% CI 0.77–0.96), sensitivity of 84%, and specificity of 90%. Conclusion: An integrated circulating signature encompassing post-transcriptional regulation, epithelial shedding, and tumor-associated protein release may support noninvasive early detection of breast cancer. Diagnostic performance estimates should be considered exploratory pending external prospective validation in age-matched cohorts.